Reaction Biology and Cisbio Bioassays sign distribution agreement

MALVERN, Pa. and CODOLET, France, Jan. 20, 2014 /PRNewswire/ -- Reaction Biology Corporation ("RBC"), a leading contract research organization providing early stage drug discovery services, announced that it has signed an agreement for Cisbio Bioassays, a cutting-edge biotechnology company in the field of products and services for human in vitro diagnostics and pharmaceutical research, to distribute its epigenetic proteins.

(Logo: http://photos.prnewswire.com/prnh/20120424/NY92966LOGO)
(Logo: http://photos.prnewswire.com/prnh/20140120/NY48461LOGO)

RBC manufactures one of the largest collections of recombinant human epigenetic proteins.  These proteins modulate genetic function in humans and are the subject of intense research in the pharmaceutical industry to validate them as targets for a new generation of cancer drugs.  Cisbio develops and markets a broad selection of assays used worldwide by researchers in drug discovery.  The company has recently expanded its product offering with very innovative solutions to assess epigenetic targets such as methyltransferases.  The new agreement will give Cisbio worldwide rights to co-market and sell RBC's proteins.

"RBC's portfolio of epigenetic proteins is projected to grow to over 200 this year," said Dr. Haiching Ma, RBC Chief Scientific Officer.  "With more and more international interest, we felt a relationship with an outstanding distributor like Cisbio would bring these proteins to the widest possible client base."

"We have been seeing increasing demand for high quality epigenetic proteins that can be included in the assays that we currently develop," added Patrick Seguin, VP Sales and Marketing.  "RBC's proteins have met all of our requirements for purity and activity levels, and this agreement represents one step forward in our goal to become a premier provider of epigenetic assays."

About Reaction Biology Corporation
Based in Malvern, PA, RBC is a premier provider of drug screening and profiling services.  With more than 465 kinases, RBC's activity assay coverage of the kinome is the broadest in the industry.  Using its proprietary HotSpot^SM technology and other innovations, RBC is expanding its already substantial production of epigenetic regulatory enzymes.  RBC has provided its services and proteins to over 450 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.

About Cisbio Bioassays
Cisbio Bioassays develops and markets products and technologies used for in vitro diagnostics and drug discovery.  With its proprietary technology, HTRF^®, the company is a leader in homogeneous fluorescence detection methods, and offers first class assays and services for drug discovery researchers.  In addition, Cisbio Bioassays provides a broad range of immunoassays for in vitro diagnostics, mainly tailored for cancerous pathologies, as well as metabolic and auto-immune diseases.

Based in Codolet, France, Cisbio Bioassays owns facilities in Bedford, MA, U.S.A., and Shanghai, China, and markets its global offer through a network of distributors.

Contacts for more information:

Reaction Biology: www.reactionbiology.com
Haiching Ma, Chief Science Officer, 1-610-722-0247, [email protected]

Cisbio Bioassays: www.cisbio.com
Francois Degorce, Director, Strategic Marketing and Corporate Communication,
+33 466 791 931, [email protected]

SOURCE Reaction Biology Corporation